Galanthamine hydrobromide is a long-acting, centrally active acetylcholinesterase(AChE) inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors. IC50 Value: 410 nM Target: AChEGalanthamine hydrobromide prevents β-amyloid-induced apoptosis in SH-SY5Y and bovine chromaffin cells. Long-term administration reduces amyloid precursor protein deposition and neurodegeneration in a mouse model of Alzheimer's disease.
[1]. Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T.Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice.Psychopharmacology (Berl). 2012 Aug 30. [2]. Berkov S, Viladomat F, Codina C, SuÁrez S, Ravelo A, Bastida J.GC-MS of amaryllidaceous galanthamine-type alkaloids.J Mass Spectrom. 2012 Aug;47(8):1065-73. [3]. Park CW, Son DD, Kim JY, Oh TO, Ha JM, Rhee YS, Park ES.Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system.Int J Pharm. 2012 Oct 15;436(1-2):32-40. Epub 2012 Jul 5. [4]. Park YS, Kim SH, Kim SY, Kim YH, Lee MH, Yang SC, Shaw LM, Kang JS.Quantification of Galantamine in Human Plasma by Validated Liquid Chromatography-Tandem Mass Spectrometry using Glimepride as an Internal Standard: Application to Bioavailability Studies in 32 Healthy Korean Subjects.J Chromatogr Sci. 2012 Jun 28. [5]. Arias et al Galantamine prevents apoptosis induced by b-amyloid and thapsigargin: involvement of nicotinic acetycholine receptors. Neuropharmacology (2004) 46 103.